SIBN SI-BONE, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1459839 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.0%
TTM net income YoY37.1%
TTM EPS YoY39.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—
Margins
Gross margin79.4%
Operating margin-7.6%
Net margin-6.2%
FCF margin-1.9%
EBITDA margin-4.6%
Returns
ROE-7.7%
ROA-5.6%
ROIC (approx.)-7.2%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets28.1%
Debt / equity0.19x
Current ratio7.58x
Interest coverage-6.88x
Cash quality & payout
Operating cash flow / net income-0.44x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $200.93M | $167.18M | $138.89M | $106.41M | $90.15M |
| Cost of revenue | $41.05M | $35.06M | $29.47M | $15.71M | $10.43M |
| Gross profit | $159.88M | $132.12M | $109.42M | $90.70M | $79.72M |
| R&D expense | $17.45M | $16.56M | $15.03M | $13.63M | $12.44M |
| SG&A expense | $40.54M | $33.76M | $31.07M | $28.96M | $25.07M |
| Operating income | -$22.33M | -$35.25M | -$46.93M | -$59.61M | -$51.67M |
| Interest expense | $2.63M | $3.44M | $3.46M | $2.82M | $5.37M |
| Pretax income | -$19.09M | -$31.08M | -$43.49M | -$61.40M | -$57.03M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.90M | -$30.91M | -$43.34M | -$61.26M | -$56.57M |
| EBITDA | -$16.56M | -$30.87M | -$41.50M | -$56.16M | -$49.58M |
| EPS (basic) | -0.44 | -0.75 | -1.13 | -1.79 | -1.71 |
| EPS (diluted) | -0.44 | -0.75 | -1.13 | -1.79 | -1.71 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 42.96M | 41.47M | 38.43M | 34.20M | 33.15M |
| Balance sheet | |||||
| Cash & equivalents | $42.24M | $34.95M | $33.27M | $20.72M | $63.42M |
| Short-term investments | — | — | — | $76.57M | $83.56M |
| Receivables | $29.91M | $27.46M | $21.95M | $20.67M | $14.25M |
| Inventory | $33.90M | $27.07M | $20.25M | $17.28M | $11.50M |
| Current assets | $216.12M | $207.78M | $211.39M | $137.61M | $175.87M |
| PP&E, net | $21.30M | $20.37M | $16.00M | $15.56M | $8.99M |
| Total assets | $238.56M | $230.44M | $230.43M | $157.55M | $190.51M |
| Current liabilities | $25.28M | $27.13M | $23.46M | $21.18M | $16.89M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | $35.57M | $35.45M | $36.06M | $35.17M | $34.97M |
| Total debt | $35.57M | $35.45M | $36.06M | $35.17M | $34.97M |
| Total liabilities | $61.02M | $63.47M | $61.05M | $59.25M | $56.09M |
| Shareholders' equity | $177.53M | $166.96M | $169.38M | $98.30M | $134.42M |
| Net debt | -$6.67M | $504,000 | $2.79M | $14.45M | -$28.45M |
| Shares outstanding | 43.65M | 42.09M | 40.69M | 34.73M | 33.67M |
| Cash flow statement | |||||
| Operating cash flow | -$675,000 | -$12.43M | -$18.71M | -$41.66M | -$39.53M |
| Capital expenditure | $8.41M | $10.50M | $7.80M | $9.51M | $6.39M |
| Free cash flow | -$9.09M | -$22.92M | -$26.51M | -$51.16M | -$45.92M |
| Investing cash flow | $4.16M | $12.62M | -$59.80M | -$2.81M | $51.58M |
| Financing cash flow | $3.38M | $1.96M | $90.93M | $2.20M | -$1.71M |
| Depreciation & amortization | $5.77M | $4.38M | $5.43M | $3.45M | $2.09M |
| Stock-based compensation | $25.52M | $25.87M | $24.06M | $23.06M | $16.87M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.